Clinical Trial Search

Primary: Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] — 396 nanogram*hour/milliliter (ng*hr/mL)

Primary: Number of Participants Who Experienced at Least One Adverse Event — 4; 11; 7; 8 participants

Primary: Number of Participants Who Experienced One or More Adverse Events During the Study — 2; 6; 4; 9 participants

Primary: PK of Daptomycin — 262.4 mg*h/L

Primary: Area Under the Curve From Time Zero to 12 Hours [AUC (0-12)] for CP-690,550 — 1370; 1410 nanogram*hour/milliliter (ng*hr/mL)

Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 6; 7; 6 Participants

Primary: Change From Baseline in Time Weighted Average (TWA) Pain Intensity (PI) on a Numeric Rating Scale (NRS) Due to Self-paced Walks on Day 3 — -0.927; -1.54; -1.73 units on…

Primary: The Primary Activity Variable Was the Recurrence of Recurrent Respiratory Papillomatosis (RRP) in Bevacizumab Treated and the Un-treated Vocal Fold in the Same Patient…

Primary: Change in Endothelial Function (Reactive Hyperemia Peripheral Arterial Tonometry (RH-PAT) Index Score) — 0.06; 0.22 units on a scale — p=0.25

Primary: Number of Subjects With Greater Than Grade 3 or 4 Toxicity — 1 participants

Primary: Physical Activity (Steps/Day) — 2956; 2994 steps/day

Primary: Incidence and Severity of Ocular Adverse Event — 0 participants

Primary: The Steady State Area Under the Drug Concentration Time Curve From 0 to 12 Hours Post Dose AUC(0-12). — 157.8; 276.5; 415.3 hour*nanogram/milliliter

Primary: Pharmacokinetics: Area Under the Concentration-Time Curve From Time Zero to the Last Measureable Concentration (AUC[0-tlast]) of Prasugrel's Active Metabolite (PRAS-AM)…

Primary: Change From Baseline in Post-Prandial Glucose Area Under the Concentration-Time Curve From Time 2 to 6 Hours (AUC 2-6) After a Mixed Meal Tolerance Test (MMTT) at Day 28…